News & Views

CANCER IMMUNOTHERAPY

CAR T cells for childhood diffuse midline gliomas

Anti-GD2 chimeric antigen receptor (CAR)-modified T cells may be a new and innovative approach for the treatment of pediatric H3-K27M-mutant diffuse midline gliomas.

  • Subscribe to Nature Medicine for full access:

    $225

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    Jones, C. & Baker, S. J. Nat. Rev. Cancer 14, 651–661 (2014).

  2. 2.

    Mackay, A. et al. Cancer Cell 32, 520–537 (2017).

  3. 3.

    Lewis, P. W. et al. Science 340, 857–861 (2013).

  4. 4.

    Mount, C. W. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0006-x (2018).

  5. 5.

    Maude, S. L. et al. N. Engl. J. Med. 378, 439–448 (2018).

  6. 6.

    Ahmed, N. et al. JAMA Oncol. 3, 1094–1101 (2017).

  7. 7.

    O’Rourke, D. M. et al. Sci. Transl. Med. 9, eaaa0984 (2017).

  8. 8.

    Brown, C. E. et al. N. Engl. J. Med. 375, 2561–2569 (2016).

  9. 9.

    Yu, A. L. et al. N. Engl. J. Med. 363, 1324–1334 (2010).

  10. 10.

    Waligora, M. et al. PLoS Med. 15, e1002505 (2018).

  11. 11.

    Grasso, C. S. et al. Nat. Med. 21, 827 (2015).

Download references

Author information

Affiliations

  1. Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada

    • Vijay Ramaswamy
  2. Division of Neurosurgery, Hospital for Sick Children, Toronto, Ontario, Canada

    • Michael D Taylor

Authors

  1. Search for Vijay Ramaswamy in:

  2. Search for Michael D Taylor in:

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Michael D Taylor.